

Sisram Medical is Increased the Shares by the Controlling Shareholder Fosun Pharma, Demonstrating Shareholder's Strong Confidence

(Hong Kong, 6th January 2022), Sisram Medical Ltd (“Sisram Medical”; stock code: 1696.HK; together with its subsidiaries referred as the “Group”), an operational holding company specializing in medical aesthetics technology for wellness, was pleased to announce that Ample Up Limited and its subsidiaries (excluding the Company) (“Ample Up”), a shareholder of the Company and a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (“Fosun Pharma”), plans to make on-market purchases of the Company’s shares (“Shares”) for not more than 1% of the total number of issued Shares within a period of six months from the date of 29 December 2021.

As of 6 January 2022, Ample Up made on-market purchases of 465,200 Shares at an average price of HK\$ 8.75 per share. It shows that the controlling Shareholder Fosun Pharma has strong confidence towards Sisram Medical. As a core member of Fosun Pharma’s medical device sector, Sisram Medical has focused on its wellness eco-system strategy, strengthened its global commercialization network, enhancing its wellness eco-system and supporting industry led by R&D breakthroughs.

About Sisram Medical Ltd

Sisram Medical Ltd (1696.HK) is the global leading provider of energy-based surgical and medical aesthetics solutions. The company is majority held by Fosun Pharma, a leading healthcare group in China. Sisram Medical successfully went public on September 19, 2017, as the first Israeli company listed on the Hong Kong Exchange Main Board. Sisram Medical’s core subsidiary, Alma, is a global leading provider of energy-based surgical and medical aesthetics solutions and is active across over 90 countries and jurisdictions worldwide. Flagship systems of Sisram Medical include (i) the “Soprano” family, primarily used for laser hair removal; (ii) the “Harmony” family, a versatile multi-application platform that can be used to treat more than 65 different FDA-cleared indications; (iii) the “Accent” family, primarily used for body contouring and skin tightening; (iv) “FemiLift”, a minimally invasive treatment system for various feminine conditions; and (v) “BeautiFill” by LipoFlow platform, the first and only energy-based device cleared by the FDA for autologous fat grafting. In addition, Sisram Medical also entered the injectables market, with products available in Israel, Hong Kong and India.

Sisram Medical – Enhancing Quality of Life

<http://www.sisram-medical.com>



复锐医疗科技 (1696.HK)

For media inquiries, please contact:

Ever Bloom (HK) Communications Consultants Group Limited

Orianna Ou / Charles Chui

+852 3468 8171 / 3468 8427

sisrammed.list@everbloom.com.cn